Vanguard Capital Management
ALLO icon

Vanguard Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Vanguard Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3M Buy
12,166,636
+5,245,286
+76% +$11.5M ﹤0.01% 2312
2026
Q1 		$16.9M Buy
+6,921,350
New +$13.9M ﹤0.01% 2441

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management's ALLO Position: Q2 2026 in Review

Vanguard Capital Management increased its Allogene Therapeutics (ALLO) stake by 76% in Q2 2026, buying an estimated $11.5M and bringing the position to 12,166,636 shares worth $25.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2312.

Vanguard Capital Management first reported a position in ALLO in Q1 2026 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Vanguard Capital Management held 12,166,636 shares of Allogene Therapeutics worth $25.3M as of Q2 2026.
  • Vanguard Capital Management bought 5,245,286 Allogene Therapeutics shares in Q2 2026, an estimated $11.5M.
  • Allogene Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2312 holding.
  • Vanguard Capital Management first reported a position in Allogene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.